Cartel Lifescience Profile
Key Indicators
- Authorised Capital ₹ 9.85 Cr
as on 01-11-2024
- Paid Up Capital ₹ 9.85 Cr
as on 01-11-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 39.00 Cr
as on 01-11-2024
- Revenue %
(FY 2023)
- Net Worth 4663.95%
(FY 2023)
- Total Assets 4959.76%
(FY 2023)
About Cartel Lifescience
The Corporate was formerly known as Cartel Hygiene Products Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.85 Cr and a paid-up capital of Rs 9.85 Cr.
The company currently has active open charges totaling ₹39.00 Cr.
Vikash Agrawal, Ashok Agrawal, Akriti Agarwal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U33100CT2020PTC010744
- Company No.
010744
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chhattisgarh
Industry
Company Details
- Location
Raipur, Chattisgarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Cartel Lifescience?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Utkarsh Bhawsinka  | Director | 23-Jun-2022 | Current |
| Vikash Agrawal | Director | 03-May-2022 | Current |
| Ashok Agrawal | Director | 15-Oct-2020 | Current |
| Akriti Agarwal | Director | 23-Jun-2022 | Current |
| Parmanand Agrawal | Director | 23-Jun-2022 | Current |
Financial Performance of Cartel Lifescience.
Cartel Lifescience Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 4663.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Cartel Lifescience?
In 2023, Cartel Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zumanix Remedies Private LimitedActive 11 years 7 monthsVikash Agrawal, Akriti Agarwal and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Aug 2023 | ₹39.00 Cr | Open |
How Many Employees Work at Cartel Lifescience?
Cartel Lifescience has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cartel Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cartel Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED.webp){kind=small}
